Author

David T. O. Yeung

Royal Adelaide HospitalORCID 0000-0002-7558-9927Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:clinical cohort / trial· 1 Approach:deep learning· 1

Frequent Co-Authors

Timothy P. HughesiD· 3 shared Agnes S. M. YongiD· 2 shared Charles T. H. ChuahiD· 2 shared Deborah L. WhiteiD· 2 shared Elyse C. PageiD· 2 shared Kian Leong LeeiD· 2 shared Naranie ShanmuganathaniD· 2 shared S. Tiong OngiD· 2 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Timothy P. HughesORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mitochondrial DNA Mutations Determine Favourable Molecular Responses to Targeted Kinase Inhibitor Therapy and Impair Oxidative Phosphorylation

Ilaria Stefania Pagani, Vaidehi Krishnan, John F. Ouyang, Chung Hoow Kok, BeiJun Chen, Kian Leong Lee, Cong M Pham, Paul Wang, Elyse C. Page, Phuong Dang, Verity A Saunders, Jane James, Kelly SY Lim, Naranie Shanmuganathan, Agnes S. M. Yong, , David M. Ross

This study shows that mitochondrial DNA mutations are linked to better responses to kinase inhibitor therapy and reduced oxidative phosphorylation in CML patients.

bioRxiv · Jul 15, 2025 · PreprintCancer Biology

The STAMP inhibitor asciminib is a new treatment option for ABL-rearranged ALL revealing a novel role for the 5' fusion partner in determining drug response

Laura N Eadie, Daniel P. McDougal, Elias Lagonik, Caitlin E Schutz, Tace S Conlin, Elyse C. Page, Jacqueline A. Rehn, John B. Bruning, Andrew S. Moore, David T. O. Yeung, Timothy P. Hughes, Deborah L. White

This study shows asciminib effectively treats NUP214::ABL1 ALL in preclinical models by inhibiting ABL1 kinase and improving survival.

bioRxiv · May 6, 2025 · PreprintCancer Biology

Single-cell transcriptomics-guided development of flow cytometric tests predicting chronic myeloid leukemia blast crisis transformation at chronic phase diagnosis

Mengge Yu, Vaidehi Krishnan, Pavithra Shyamsundar, Kian Leong Lee, Florian Schmidt, Xi Ren, Charles T. H. Chuah, Shyam Prabhakar, Verity A Saunders, David T. O. Yeung, Naranie Shanmuganathan, Agnes S. M. Yong, Timothy P. Hughes, S. Tiong Ong

The paper develops flow cytometry tests to predict blast crisis transformation in chronic myeloid leukemia patients using single-cell transcriptomics insights.

bioRxiv · Jan 9, 2025 · PreprintCancer Biology